Brief: SAB Biotherapeutics Appoints Michael G. King Jr. As Chief Financial Officer
24/10/2023 13:01
Oct 24 (Reuters) - SAB Biotherapeutics Inc SABS.O :
* SAB BIOTHERAPEUTICS APPOINTS MICHAEL G. KING JR. AS CHIEF
FINANCIAL OFFICER
* SAB BIOTHERAPEUTICS -KING, WHO STARTS HIS NEW ROLE ON OCT.
30,
REPLACES RUSSELL BEYER, WHO IS EXPECTED TO STEP DOWN ON NOV. 15
Source text for Eikon: ID:nGNX8jgz5F
Further company coverage: SABS.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies